About Molecular Partners
Molecular Partners is a publicly listed company based in Zurich (Switzerland) founded in 2004. Therapeutic solutions for diseases are developed using DARPin technology. It operates on a HealthTech model. Molecular Partners has raised $59.94 million across 3 funding rounds from investors including Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures. The company has 174 employees. Its website molecularpartners.com draws about 12 thousand monthly visits. Molecular Partners offers products and services including DARPin Therapeutics, MP0533, MP0712, and MP0317. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Molecular Partners AG.
Company details
Molecular Partners is engaged in the development of innovative DARPin therapeutics targeting cancer and other serious diseases. The company operates within the biotechnology sector, focusing on solutions like radiopharmaceuticals, immune cell engagers, and multispecific therapies. Programs such as MP0533 for AML, MP0712 for Radio DARPin Therapy, and MP0317 for solid tumors are being advanced. Platforms like Switch-DARPin for conditional immune activation are also utilized to address unmet medical needs in oncology.
- Headquarters Zurich, Switzerland
- Employees 174
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website molecularpartners.com
- Social LinkedIn X
- Legal Name Molecular Partners Ag
- Net Profit-$77.77 M (USD)-14.08as on Dec 31, 2025
- EBITDA-$67.23 M (USD)9.44as on Dec 31, 2025
- Total Equity Funding$59.94M (USD)
in 3 rounds
- InvestorsIndex Ventures
& 4 more
- Employee Count174
Products & Services of Molecular Partners
Molecular Partners offers a comprehensive portfolio of products and services, including DARPin Therapeutics, MP0533, MP0712, and MP0317.
Innovative therapies are developed using DARPin platform technology.
Tetra-specific T cell engager is designed for AML.
Radio DARPin Therapy is targeted at DLL3 protein.
Multispecific DARPin is developed for tumor-localized activation.
Funding Insights of Molecular Partners
Molecular Partners has successfully raised a total of $59.94M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59.94M
- Total Rounds 3
- First Round $15.4M
(Aug 2007)
- Investors Count 5
All 3 funding rounds of Molecular Partners with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | Post-IPO | – | – | – | |
| Dec 2009 | $44.54M | Series B | – | – | |
| Aug 2007 | $15.4M | Series A | – | Index Ventures |
5 investors in total: 5 institutional.
Investors in Molecular Partners
Molecular Partners has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology startups and entrepreneurs. | indexventures.com | |||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
| bbbiotechventures.com | ||||
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States |
Investor details for Molecular Partners
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Molecular Partners
71 people are tracked at Molecular Partners (34 in leadership, 7 in board & advisors, 30 in team); the tracked headcount is 174.
| Name | Role | Group |
|---|---|---|
Patrick Amstutz | CEO & Director | Leadership |
Gabriel Sigrist | Associate Director USP | Leadership |
Bartek Jarosz | Director, Outsourcing And Vendor Management | Leadership |
Christiane Andrieu | Associate Director Clinical Science | Leadership |
Christian Lizak | Senior Director Radiotherapeutics | Leadership |
Baris Arican | VP, Information Technology | Leadership |
Alexander Zürcher | COO | Leadership |
Robert Hendriks | VP, Finance | Leadership |
Federica Sgariglia | Director Of New Product Planning | Leadership |
Vladimir Kirkin | Vice President Development Project Leader | Leadership |
Nicolas Hochuli | Head Of Total Rewards / HRBP | Leadership |
Laura Jeanbart | Director, Portfolio Management & Communications | Leadership |
Andrew Knox | Director - New Product Planning | Leadership |
Philippe Legenne | Chief Medical Officer | Leadership |
Michael Sanderson | Senior Director, Head Of Translational Medicine | Leadership |
Marianne Soergel | Head Drug Safety | Leadership |
Matteo Bianchi | Associate Director Oncology Research | Group & Biology Lead | Leadership |
Christian Reichen | Associate Director Oncology Research | Leadership |
Kyriaki Ioannou | Associate Director, Translational Medicine | Leadership |
Lorena Vega Hernández | Director European Patent Attorney | Leadership |
51 more people are available in the full profile.
Complete people profiles for Molecular Partners
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Molecular Partners
Molecular Partners is a publicly listed company on the SIX with ticker symbol MOLN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2021
- Listed onNASDAQ: MOLN
- Listed entityMolecular Partners AG
- Exchange sectorHealth technology
- ISINCH0256379097
- Share price3.17 CHF (-1.86% on the day) · 2026-05-11
- Market capitalisation130,410,093.00 CHF
- EPS (diluted, trailing year)-1.65 CHF
- Volume (last session)1,965
- Analyst consensusBuy
Financials of Molecular Partners
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -61.6M CHF | -53.3M CHF | |
| 2024 | 5.0M CHF | -54.0M CHF | -58.9M CHF |
| 2023 | 7.0M CHF | -62.0M CHF | -58.7M CHF |
| 2022 | 189.6M CHF | 117.8M CHF | 119.0M CHF |
| 2021 | 9.8M CHF | -63.8M CHF | -60.9M CHF |
Detailed financial statements for Molecular Partners
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Molecular Partners
4 dated milestones of Molecular Partners across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Molecular Partners is founded.
- Funding First funding round of $15.4M.
- Funding Latest funding round, Post-IPO,.
- IPO Lists on the stock exchange (IPO).
Web traffic of Molecular Partners
The website of Molecular Partners (molecularpartners.com) receives about 12.3K visits a month and ranks #2,658,648 among all websites worldwide, #3,623 in Biotechnology and Pharmaceuticals.
- Monthly visits12.3K
▲ 46.3% vs previous month
- Unique visitors2.6K
per month
- Global rank#2,658,648
among all websites
- Category rank#3,623
Health · Biotechnology and Pharmaceuticals
- Bounce rate61%
- Pages per visit1.6
- Average visit42 sec
- DevicesDesktop 65% · Mobile 35%
Websites whose visitors overlap most with Molecular Partners. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| swissbiotech.org | 100% | 63.9K | #658,452 | View details | |
| curetis.com | 84% | View details | |||
| molprofiles.co.uk | 83% | View details | |||
| adocia.com | 83% | 2.2K | #3,636,776 | View details | |
| monterosatx.com | 83% | 27.7K | #1,555,357 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Molecular Partners
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Molecular Partners
Complete news archive for Molecular Partners
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Molecular Partners
Molecular Partners was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Molecular Partners is headquartered in Zurich, Switzerland.
Molecular Partners is a funded company, having raised a total of $59.94M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15.4M, raised on Aug 2007.
Molecular Partners has 174 employees.
Molecular Partners is engaged in the development of innovative DARPin therapeutics targeting cancer and other serious diseases. The company operates within the biotechnology sector, focusing on solutions like radiopharmaceuticals, immune cell engagers, and multispecific therapies. Programs such as MP0533 for AML, MP0712 for Radio DARPin Therapy, and MP0317 for solid tumors are being advanced. Platforms like Switch-DARPin for conditional immune activation are also utilized to address unmet medical needs in oncology.
Molecular Partners offers DARPin Therapeutics, MP0533, MP0712, and MP0317.
Yes, Molecular Partners is publicly traded on SIX under the ticker symbol MOLN.
Molecular Partners has 5 investors. Key investors include Index Ventures, Johnson & Johnson Innovation – JJDC, BB Biotech Ventures, Endeavour Vision, and EW Healthcare Partners.
Molecular Partners operates through Molecular Partners Ag.